Loading
A phase 1/2 trial of Belzupacap sarotalocan run by Aura Biosciences, completed.
Study in Subjects With Small Primary Choroidal Melanoma is a phase 1/2 interventional study registered as NCT03052127 by Aura Biosciences, with 57 participants enrolled, started 2017-02-27. Conditions recorded: Uveal Melanoma, Ocular Melanoma and Choroidal Melanoma. Interventions recorded: Light-activated AU-011 and Laser Activation.
Shares Aura Biosciences, Belzupacap sarotalocan, Uveal melanoma and the tag pipeline.
Shares Aura Biosciences, Belzupacap sarotalocan, Uveal melanoma and the tag pipeline.
Shares Aura Biosciences, Belzupacap sarotalocan and the tag pipeline.
Shares Aura Biosciences, Belzupacap sarotalocan and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Shares Uveal melanoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/